Updated version of this database is available at ThpDB2

Detailed description page of THPdb

This page displays user query in tabular form.

Th1236 details
Primary information
ID1848
ThPP IDTh1236
Therapeutic Peptide/Protein NameSipuleucel-T
SequenceNA view full sequnce in fasta
Functional ClassificationIIIc
Molecular WeightNA
Chemical FormulaNA
Isoelectric PointNA
HydrophobicityNA
Melting Point (℃)NA
Half LifeNA
Description Sipuleucel-T is a personalized, autologous, cellular immunotherapy. Sipuleucel-T is a therapeutic cancer vaccine for prostate cancer. Sipuleucel-T selectively targets the prostate-specific antigen (PSA) known as prostatic acid phosphatase (PAP) that is expressed in around 95% of prostate cancers. It must be prepared specifically for each patient. In metastatic prostate cancer, it has extended survival by median 4.1 months (IMPACT Phase III trial data). Sipuleucel-T is marketed under the brand name Provenge by Dendreon Corporation. Sipuleucel-T was approved by the U.S. Food and Drug Administration (FDA) on April 29, 2010, to treat asymptomatic or minimally symptomatic metastatic Hormone-Refractory Prostate Cancer (HRPC). The treatment initially cost $93,000 at the time of FDA approval, but rose to over $100,000 in 2014.
Indication/DiseaseSipuleucel-T is an autologous cellular immunotherapy indicated for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer.
PharmacodynamicsNA
Mechanism of ActionSipuleucel-T is designed to induce an immune response targeted against PAP, an antigen expressed in most prostate cancers. During ex vivo culture with PAP-GM-CSF, APCs take up and process the recombinant target antigen into small peptides that are then displayed on the APC surface. The precise mechanism remains unknown, however.
ToxicityNA
MetabolismNA
AbsorptionNA
Volume of DistributionNA
ClearanceNA
CategoriesAntineoplastic and Immunomodulating Agents
Patents NumberUS8153120
Date of Issue22/03/07
Date of Expiry22/03/27
Drug InteractionThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with 2-Methoxyethanol, 9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine, Abatacept, abetimus, ABR-215757, Acteoside, Adalimumab, Adefovir Dipivoxil, Afelimomab, Alefacept.
TargetProstatic acid phosphatase
Information of corresponding available drug in the market
Brand NameProvenge
CompanyNA
Brand DiscriptionProvenge (sipuleucel-T) contains a protein that stimulates the body's immune system to help it respond against certain cancer cells.
Prescribed forProvenge® (sipuleucel-T) is an autologous cellular immunotherapy indicated for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer
Chemical NameNA
FormulationNA
Physcial AppearanceSolution
Route of AdministrationIntravenous
Recommended DosageThe recommended course of therapy for PROVENGE is 3 complete doses, given at approximately 2-week intervals. In controlled clinical trials, the median dosing interval between infusions was 2 weeks (range 1 to 15 weeks); the maximum dosing interval has not been established
ContraindicationHypersensitivity to the active substance
Side Effectsfever;gredness, swelling, oozing, or other signs of infection where the IV needle was placed; orgsigns of infection around the veins your cells were collected from.
Useful Link http://www.rxlist.com/provenge-drug.htm , http://www.drugs.com/pro/provenge.html , https://www.cancer.gov/about-cancer/treatment/drugs/fda-sipuleucel-T
PubMed ID16752945, 26025563, 15176049, 16736512
3-D StructureN.A.